The earliest pivotal CAR-T trial for R/R DLBCL, utilizing CD19-targeted CAR-T with CD28 costimulatory domain. The ZUMA series has advanced to ZUMA 9 and real-world research, enrolling over 295 patients. Key findings: CD28-based CAR-T triggers rapid, severe cytokine release syndrome (CRS); 32% of patients required ICU admission for CRS. Re-administering identical CAR-T cells to partial response (PR) patients fails to boost efficacy.

Genetic testing is indispensable for hematological disease management. For acute leukemia, it supports diagnosis, prognosis assessment and treatment guidance. However, interpreting genetic mutation reports is highly complex. Clinicians must distinguish germline (inherited) mutations from somatic tumor-derived variants, clarify whether germline variants contribute to leukemia susceptibility, analyze mutation loci, variant combinations, and their impacts on prognosis and target

Genetic testing plays a vital role in diagnosing and treating hematologic malignancies. It enables precise disease classification, prognostic stratification, and personalized treatment planning, guiding targeted therapies and minimizing adverse reactions. By detecting gene mutations and monitoring minimal residual disease (MRD), it helps assess relapse risks and improve patient outcomes.

MICM integrated diagnosis covers Morphology (M), Immunology (I), Cytogenetics (C) and Molecular biology (M), serving as the core diagnostic system for hematological malignancies. Its updated scope also incorporates two additional P modules: Pathogen detection and Pharmacogenomics (MICM-PP). Director Tong Chunrong from Beijing Boren Hospital elaborates on how this integrated system enables precise subtyping and individualized therapy for blood cancers.

Wondering why leukemia patients need genetic testing? Director Zheng Qinlong explains its vital role in precision hematology care. Genetic heterogeneity drives varied chemo responses; gene sequencing guides targeted therapy, MRD surveillance and risk stratification. Comprehensive molecular profiling avoids ineffective regimens, cuts costs and enables personalized long-term treatment plans.

Clinical evaluations are systematically carried out centered on five core laboratory divisions (naming varies across hospitals): Cell Morphology Laboratory, Pathological Diagnosis Laboratory, Flow Cytometry Laboratory, Cytogenetics Laboratory, and Molecular Diagnosis Laboratory. Corresponding tests include cell morphology and cytochemical staining, pathology and immunohistochemistry, flow cytometry, karyotype analysis, FISH, gene testing, etc.